DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0184245 A1 Eberting (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0184245 A1 Eberting (43) Pub US 2016O184245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0184245 A1 Eberting (43) Pub. Date: Jun. 30, 2016 (54) FORMULATIONS FOR EPIDERMAL REPAIR A647/8 (2006.01) A61K 8/44 (2006.01) (71) Applicant: Cheryl Lee EBERTING, Alpine, UT A647/24 (2006.01) (US) A618/55 (2006.01) A613 L/455 (2006.01) (72) Inventor: Cheryl Lee Eberting, Alpine, UT (US) A618/49 (2006.01) A613 L/19 (2006.01) A619/00 2006.O1 (22) PCT Filed: Jul. 25, 2014 A61O 19/00 :08: A618/42 (2006.01) (86). PCT No.: PCT/US1.4/48226 (52) U.S. Cl. S371 (c)(1), CPC ................. A61 K31/164 (2013.01); A61K 8/42 (2) Date: Jan. 25, 2016 (2013.01); A61 K3I/575 (2013.01); A61K 8/63 (2013.01); A61 K3I/20 (2013.01); A61K 8/361 Related U.S. Application Data (2013.01); A61 K3I/23 (2013.01); A61K 8/37 (60) Provisional application No. 61/858,513, filed on Jul. (2013.01); A61 K3I/133 (2013.01); A61K 8/41 25, 2013, provisional application No. 61/896,215, (2013.01); A61 K47/12 (2013.01); A61K 8/365 filed on Oct. 28, 2013, provisional application No. (2013.01); A61 K47/183 (2013.01); A61K 8/44 61/968,078, filed on Mar. 20, 2014, provisional appli- (2013.01); A61 K47/24 (2013.01); A61K 8/55 cation No. 62/005,702, filed on May 30, 2014. (2013.01); A61 K3I/455 (2013.01); A61 K 8/4926 (2013.01); A61K 31/19 (2013.01); Publication Classification A6 IK3I/573 (2013.01); A61 K9/0014 (2013.01); A61O 19/007 (2013.01); A61 K (51) Int. Cl. 2800/5922 (2013.01); A61 K 2800/48 (2013.01) A6 IK3I/64 (2006.01) A 6LX3/575 (2006.01) (57) ABSTRACT A6 IK 8/63 (2006.01) A6 IK3I/20 (2006.01) The present disclosure is directed to dermatological formu A6 IK 8/36 (2006.01) lations and their use for treating a variety of dermatological A6 IK3I/23 (2006.01) diseases and disorders, and for repairing and restoring a dis A6 IK S/37 (2006.01) rupted epidermal barrier, inhibiting inflammation, restoring a A6 IK3I/33 (2006.01) proper environment for maintaining a balanced symbiotic A6 IK 8/4I (2006.01) microbiome, and inhibiting the growth of pathogenic micro A6 IK 47/12 (2006.01) organisms in the epidermis—the outer layer of mammalian A6 IK 8/365 (2006.01) skin. Patent Application Publication Jun. 30, 2016 Sheet 1 of 2 US 2016/0184245 A1 Patent Application Publication Jun. 30, 2016 Sheet 2 of 2 US 2016/O184245 A1 &r / & s S US 2016/0184245 A1 Jun. 30, 2016 FORMULATIONS FOR EPIDERMAL REPAIR 0005. The stratum corneum of the epidermis is primarily responsible for the water permeability barrier function of the TECHNICAL FIELD skin, which is critical for preventing excessive dryness of the skin, as well as dehydration of the underlying tissues. Three 0001. The present disclosure is directed to dermatological main factors contribute to the establishment of this water formulations and their use for repairing and restoring a dis permeability barrier within the stratum corneum: First, the rupted epidermal barrier. The disclosed formulations are intercellular, hydrophobic lipids form the only continuous designed to Supplement and replenish the natural lipid com pathways through the stratum corneum, and thereby block the ponents of the epidermis, inhibit inflammation, restore the transport of water molecules. Second, the corneocytes, which conditions required for maintaining a balanced symbiotic are surrounded by hydrophobic envelopes, are tightly linked epidermal microbiome, and inhibit the growth of pathogenic to each other by specialized connective organelles known as microorganisms in the epidermis—the outer layer of mam corneodesmosomes. Third, the intracellular and extracellular malian skin. The disclosed formulations are useful for the hygroscopic materials known as natural moisturizing factors treatment of Subjects suffering from skin or mucous mem brane disturbances characterized by epidermal disruption, specifically retain water in the outer layer of the stratum inflammation, and, in some embodiments, Superinfection COCl. with pathogenic microorganisms. 0006 Moreover, the intercellular lipids in the stratum cor neum of human skin form two lamellar phases (extended lamellar sheets of ordered lipid molecules) in two planes that BACKGROUND lie parallel to the skin surface, with repeat distances of 0002 Human skin is composed of several morphologi approximately 6 and 13 nm. These lamellar phases are cally distinct layers. The outer-most layer of the skin, the respectively referred to as the short periodicity phase and the epidermis, is composed of 4 to 5 sub-layers depending on long periodicity phase. Within these lamellar phases the lipids where on the body the skin is located. These sub-layers, from are highly organized in a tightly-packed, mostly lateral, the outer-most layer to the inner-most layer, include the Stra orthorhombic state. The orthorhombic packing, in addition to tum corneum, the stratum lucidum (which is present only in the presence of the long periodicity phase, is thought to be thick skin, Such as the Soles of feet and palms of hands), the critical for normal barrier function. stratum granulosum, the stratum spinosum and the stratum 0007. It is believed that the long alkyl chains of the fatty basale. acids and lipids within the lipid matrix of the stratum corneum 0003. The underlying layers of the epidermis are referred are needed to induce the formation of the orthorhombic lattice to as the "viable epidermis, and form a dynamic, constantly observed in mixtures of ceramides and cholesterols. Further self-renewing tissue that ultimately generates the stratum cor more, it has been shown, using tape stripping and electron neum—the layer exposed to the external environment. Skin microscopy that this highly organized lipid lamellar phase is cells, known as keratinocytes, grow and divide within the missing from between the corneocytes in the outer most lay basal layer, and undergo a number of changes in both struc ers of dry skin. ture and composition as they migrate outwards through the 0008. From the above, it is clear that the human epidermis stratum spinosum and stratum granulosum to the stratum comprises a complex and heterogeneous mix of lipids, pre corneum, ultimately differentiating into corneocytes, which dominantly consisting of Saturated lipids, cholesterol, and make up the stratum corneum. cholesterolesters, and long-chained fatty acids, with the satu 0004 Corneocytes of the stratum corneum are flat, dead rated lipids being primarily a complex mixture of different cells comprised mostly of keratin filaments and water, and types of ceramides. This heterogeneous mix of lipids is Surrounded by a densely cross-linked protein layer (the largely responsible for the “epidermal barrier' formed by “cornified envelope') that is, in turn, chemically linked to a healthy human skin. lipid envelope. The lipid envelope acts as an interface 0009. A healthy, intact epidermal barrier plays a vital role between the Stacked layers of corneocytes, forming a lipo in protecting mammals, and particularly humans, from the philic and non-polar layer between the hydrophilic corneo outside world. It serves as a physical barrier to simulta cytes. The intercellular lipid layers between layers of corneo neously prevent the entry of harmful pathogens, irritants, cytes are a complex matrix consisting of a wide variety of allergens and other noxious chemical species, and the exit of ceramides, cholesterol, cholesterol esters, and free fatty excessive amounts of water, thereby providing protection acids. Although estimates vary, one study using advanced and from infection, irritation and dehydration. Moreover, healthy carefully controlled methods revealed these lipid layers com human skin, with its intact epidermal barrier, plays an impor prise, on average, about 47% ceramides; 24% cholesterol: tant role in thermoregulation, and provides a relatively strong 18% cholesterol esters; and 11% fatty acids, by weight. exterior layer that is resistant to physical damage by abrasion (Norlen, et al., Inter- and intra-individual differences in or puncture. human stratum corneum lipid content related to physical 0010. In contrast, a disrupted and dysfunctional epidermal parameters of skin barrier function in vivo. J. Invest. Derma barrier is a hallmark of atopic dermatitis, Xerosis, ichthyosis, tol. 1999 January; 112(1): 72-7.) The vast majority of these irritant dermatitis, allergic contact dermatitis, dyshidrosis, lipids arise from the secretory organelles, known as lamellar Seborrheic dermatitis, psoriasis, all forms of cutaneous lupus bodies, or lamellar granules, within keratinocytes. These erythematosus (CLE) including acute, Subacute, and chronic lamellar granules fuse with the cell membrane and release cutaneous lupus, rosacea, acne, and many other papulosqua their contents into the extracellular space once the kerati mous skin disorders. Similarly, it appears that a disrupted and nocytes reach the stratum granulosum?stratum corneum dysfunctional epidermal barrier is a hallmark of many, if not interface. Following their release, these lipids self-organize all, forms of photodermatoses, including idiopathic, genetic, into the lamellar sheets that are a distinctive molecular char metabolic and exogenous photodermatoses. It is widely acteristic of the stratum corneum. believed that such a dysfunctional barrier can result from a US 2016/0184245 A1 Jun. 30, 2016 perturbation—deficiency, Surplus or alteration—of the lipid esters of fatty acids disclosed herein, in the presence or species that are normally present in an intact, healthy epider absence of 183-glycyrrhetinic acid and/or a glucocorticoid mis. Additionally, abnormalities in the descquamation of the and/or niacinamide, to establish and maintain an acidic pH epidermis, an overly exuberant inflammatory process, or the within the epidermis that is important for treating epidermal loss or imbalance of the naturally occurring antibacterial barrier defects and/or repairing, replenishing or maintaining lipids within the epidermis, have been implicated in a subset an effective epidermal barrier.
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
    Article AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes Ju-Hyun Kim 1, Soon-Sang Kwon 1, Tae Yeon Kong 1, Jae Chul Cheong 2, Hee Seung Kim 2, Moon Kyo In 2 and Hye Suk Lee 1,* 1 Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon 14662, Korea; [email protected] (J.-H.K.); [email protected] (S.-S.K.); [email protected] (T.Y.K.) 2 Forensic Chemistry Laboratory, Forensic Science Division, Supreme Prosecutor’s Office, 157 Banpo-daero, Seocho-gu, Seoul 06590, Korea; [email protected] (J.C.C.); [email protected] (H.S.K.); [email protected] (M.K.I.) * Correspondence: [email protected]; Tel.: +82-2-2164-4061 Academic Editor: Diego Muñoz-Torrero Received: 22 February 2017; Accepted: 8 March 2017; Published: date Abstract: AM-2201 is a synthetic cannabinoid that acts as a potent agonist at cannabinoid receptors and its abuse has increased. However, there are no reports of the inhibitory effect of AM-2201 on human cytochrome P450 (CYP) or uridine 5′-diphospho-glucuronosyltransferase (UGT) enzymes. We evaluated the inhibitory effect of AM-2201 on the activities of eight major human CYPs (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and six major human UGTs (1A1, 1A3, 1A4, 1A6, 1A9, and 2B7) enzymes in pooled human liver microsomes using liquid chromatography–tandem mass spectrometry to investigate drug interaction potentials of AM-2201. AM-2201 potently inhibited CYP2C9-catalyzed diclofenac 4′-hydroxylation, CYP3A4-catalyzed midazolam 1′-hydroxylation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-glucuronidation, and UGT2B7-catalyzed naloxone 3-glucuronidation with IC50 values of 3.9, 4.0, 4.3, and 10.0 µM, respectively, and showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation with a Ki value of 2.1 µM.
    [Show full text]
  • Biliary Bile Acid Composition of the Human Fetus in Early Gestation
    0031-3998/87/2102-0197$02.00/0 PEDIATRIC RESEARCH Vol. 21, No.2, 1987 Copyright© 1987 International Pediatric Research Foundation, Inc. Printed in U.S.A. Biliary Bile Acid Composition of the Human Fetus in Early Gestation C. COLOMBO, G. ZULIANI, M. RONCHI, J. BREIDENSTEIN, AND K. D. R. SETCHELL Department q/Pediatrics and Obstetrics, University q/ Milan, Milan, Italy [C. C., G.Z., M.R.j and Department q/ Pediatric Gastroel1/erology and Nwrition, Children's Hospital Medical Center, Cincinnati, Ohio 45229 [J.B., K.D.R.S.j ABSTRACf. Using analytical techniques, which included the key processes of the enterohepatic circulation of bile acids capillary column gas-liquid chromatography and mass ( 16-19). As a result of physiologic cholestasis, the newborn infant spectrometry, detailed bile acid profiles were obtained for has a tendency to develop a true neonatal cholestasis when 24 fetal bile samples collected after legal abortions were subjected to such stresses as sepsis, hypoxia, and total parenteral performed between the 14th and 20th wk of gestation. nutrition ( 15). Qualitatively, the bile acid profiles of all fetal bile samples Abnormalities in bile acid metabolism have been suggested to were similar. The predominant bile acids identified were be a factor in the development of certain forms of cholestasis in chenodeoxycholic and cholic acid. The presence of small the newborn (20) and in animal models the hepatotoxic nature but variable amounts of deoxycholic acid and traces of of bile acids has been well established (21-24). A greater under­ lithocholic acid suggested placental transfer of these bile standing of the etiology of these conditions requires a better acids from the maternal circulation.
    [Show full text]
  • TRANSPARENCY COMMITTEE Opinion 19 February 2014
    The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 ORPHACOL 50 mg, hard capsule B/30 (CIP 34009 416 886 0 7) B/60 (CIP 34009 416 887 7 5) ORPHACOL 250 mg, hard capsule B/30 (CIP: 34009 416 890 8 6) Applicant: CTRS INN cholic acid ATC Code (2012) A05AA03 (Bile acid preparations) Reason for the Inclusion request List concerned Hospital use (French Public Health Code L.5123-2) "Treatment of inborn errors in primary bile acid synthesis due to 3β-hydroxy-∆5-C -steroid oxidoreductase deficiency or ∆4-3-oxosteroid- Indication concerned 27 5β-reductase deficiency in infants, children and adolescents aged 1 month to 18 years and adults." HAS - Medical, Economic and Public Health Assessment Division 1/20 Actual Benefit Substantial. The benefits of using cholic acid in the treatment of inborn errors in primary 5 bile acid synthesis due to 3 β-hydroxy-∆ -C27 -steroid oxidoreductase deficiency or ∆4-3-oxosteroid-5β-reductase deficiency as soon as they are diagnosed have been established since 1993, when the first hospital preparation was made available in France by the AP-HP [Paris public hospital system], followed by temporary authorisations for use by a named patient [ATU nominative in French] since 2007. In particular, none of the 20 patients followed in France and treated with cholic acid since this date have needed a liver transplant, the only other treatment option. Treatment Improvement in with cholic acid allows postponing liver transplantation and improving Actual Benefit overall symptomatology, normalising lab work results and improving histological liver lesions, with good safety.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux
    JPET Fast Forward. Published on February 27, 2018 as DOI: 10.1124/jpet.117.246033 This article has not been copyedited and formatted. The final version may differ from this version. JPET#246033 Title Page FXR Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms Cen Guo, Carl LaCerte, Jeffrey E. Edwards, Kenneth R. Brouwer, Kim L.R. Brouwer Collaborators: Kimberly M. Freeman, Jonathan P. Jackson Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Downloaded from University of North Carolina at Chapel Hill, Chapel Hill, NC (C.G., K.L.R.B.); Intercept Pharmaceuticals (J.E., C.L.), Qualyst Transporter Solutions, Durham, NC (K.R.B., K.M.F., J.P.J.) jpet.aspetjournals.org at ASPET Journals on September 30, 2021 1 JPET Fast Forward. Published on February 27, 2018 as DOI: 10.1124/jpet.117.246033 This article has not been copyedited and formatted. The final version may differ from this version. JPET#246033 Running Title Page Running Title: FXR Agonists Increase Bile Acid Efflux in Human Hepatocytes Address correspondence to: Kim L.R. Brouwer UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill, CB #7569 Chapel Hill, NC 27599-7569 Downloaded from E-mail address: [email protected] Telephone: 919 – 962 – 7030 Fax: 919 – 962 – 0644 jpet.aspetjournals.org Number of text pages: 25 Number of tables: 1 Number of figures: 5 at ASPET Journals on September 30, 2021 Number of references: 60 Number
    [Show full text]
  • Cholic Acid and Chenodeoxycholic Acid for Treating Inborn Errors of Bile Acid Synthesis (All Ages)
    Clinical Commissioning Policy: Cholic acid and chenodeoxycholic acid for treating inborn errors of bile acid synthesis (all ages) NHS England Reference: 170127P andard Operating Procedure: Clinical Commissioning Policy: Cholic acid and chenodeoxycholic acid for treating inborn errors of bile acid synthesis (all ages) First published: July 2019 Prepared by NHS England Specialised Services Clinical Reference Group for Metabolic Disorders Publishing Approval Reference: 000826 Published by NHS England, in electronic format only. Contents Policy Statement ..................................................................................................... 4 Equality Statement .................................................................................................. 4 Plain Language Summary ...................................................................................... 5 1 Introduction ......................................................................................................... 8 2 Definitions ......................................................................................................... 11 3 Aims and Objectives ......................................................................................... 12 4 Epidemiology and Needs Assessment .............................................................. 13 5 Evidence Base .................................................................................................. 14 6 Criteria for Commissioning ...............................................................................
    [Show full text]
  • The Influence of Bile Acids Homeostasis by Cryptotanshinone-Containing Herbs
    The influence of bile acids homeostasis by cryptotanshinone-containing herbs Chengcheng Gao, Tianheng Ma, Liqun Pang, Rui Xie* Department of Gastroenterology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, Jiangsu 223300, P. R. China Abstract Background: Herbs might affect the homeostasis of bile acids through influence of multiple metabolic pathways of bile acids. Objective: To investigate the inhibition of cryptotanshinone towards the glucuronidation of LCA, trying to indicate the possible influence of cryptotanshinone-containing herbs towards the homeostasis of bile acids. Methods: The LCA-3-glucuronidation and LCA-24-glucuronidation reaction was monitored by LC-MS. Results: Initial screening showed that 100 μM of cryptotanshinone inhibited LCA-24-glucuronidation and LCA-3-glucuro- nidation reaction activity by 82.6% and 79.1%, respectively. This kind of inhibition behaviour exerted cryptotanshinone concentrations-dependent and LCA concentrations-independent inhibition behaviour. Conclusion: All these data indicated the possibility of cryptotanshinone’s influence towards bile acids metabolism and homeostasis of bile acids. Keywords: herbs, lithocholic acid (LCA), homeostasis African Health Sciences 2014;14(1): 206-210 http://dx.doi.org/10.4314/ahs.v14i1.32 Introduction X receptor (PXR) mediated-transcription regulation of Bile acids, initiated by CYP7A1-catalyzed cholesterol cytochrome 3A which has been regarded as the most oxidation in liver, exert an important role in the solubi- important enzyme involved in the metabolism of LCA lization, absorption, and transportation of dietary lipids 6. in the intestine1. The most abundant bile acids in human Besides CYP3A-catalyzed metabolism of LCA, glu- are consisted of cholic acid (CA),chenodeoxycholic acid curonidation of LCA has been regarded as another (CDCA), deoxycholic acid (DCA), and lithocholic acid important metabolic pathway of LCA.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]